However, before using compounded tirzepatide, it is important to understand the possible risks and side effects
Kindel TL, Wang AY, Wadhwa A et al (2025) Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period
Tirzepatide can potentially be reduced from maximum doses as appetite regulation normalizes
These may indicate acute cholecystitis, bile duct obstruction, or cholangitis requiring urgent intervention
Instruct patients to discontinue SOLIQUA 100/33 promptly and contact their physician if pancreatitis is suspected [see Warnings and Precautions (5.2)]
On timeline, NAD+ effects can be felt relatively quickly for some people, while many peptide driven changes build gradually